The U.S. AI diabetic retinopathy screening market is experiencing significant growth as healthcare providers increasingly adopt artificial intelligence (AI)-powered diagnostic technologies to improve early detection and management of diabetic eye diseases. Diabetic retinopathy is one of the leading causes of vision impairment among working-age adults and occurs when prolonged high blood sugar levels damage the blood vessels in the retina. Early screening and timely intervention are essential to prevent severe vision loss.

The U.S. AI-driven diabetic retinopathy screening market was valued at USD 184.15 million in 2025 and is projected to reach USD 1,081.73 million by 2034, registering a CAGR of 21.74% during the forecast period.

Market Scope

1. Increasing Adoption of AI-Based Diagnostic Technologies

The growing acceptance of artificial intelligence in healthcare is a major factor supporting the expansion of the U.S. AI diabetic retinopathy screening market. AI algorithms can analyze retinal scans, detect abnormalities, and classify disease severity, allowing healthcare professionals to identify patients who require further evaluation.

The ability of AI systems to provide rapid and consistent screening results is improving workflow efficiency in hospitals, clinics, and primary care settings.

2. Rising Diabetes Prevalence Driving Screening Demand

The increasing number of individuals living with diabetes in the United States is creating a strong need for effective diabetic retinopathy screening programs. Regular retinal examinations are essential for preventing diabetes-related blindness, increasing demand for accessible and scalable AI-powered screening solutions.

AI technologies enable broader screening coverage, particularly among patients who may have limited access to specialized eye care services.

3. Integration with Digital Healthcare Infrastructure

AI diabetic retinopathy screening platforms are increasingly integrated with electronic health records (EHRs), telemedicine platforms, and digital health systems. These integrations enable seamless data sharing, remote diagnosis, and improved coordination between healthcare providers.

The expansion of teleophthalmology services is further supporting the adoption of AI-powered retinal screening technologies across different healthcare environments.

4. Growing Focus on Early Disease Detection

Early detection is critical for preventing severe complications associated with diabetic retinopathy. AI-based screening tools help identify retinal abnormalities at earlier stages, allowing healthcare providers to initiate timely treatment strategies.

The increasing emphasis on preventive healthcare and population health management is creating favorable conditions for market expansion.

Market Opportunities

1. Expansion of AI Screening in Primary Care Settings

One of the major opportunities in the U.S. AI diabetic retinopathy screening market is the deployment of AI-based solutions in primary care facilities. Since many diabetic patients regularly visit primary care providers, integrating retinal screening capabilities into these settings can improve early detection rates.

AI-enabled screening devices can help bridge gaps caused by limited access to ophthalmology specialists.

2. Growth of Teleophthalmology Services

The increasing adoption of remote healthcare services presents significant opportunities for AI diabetic retinopathy screening solutions. Teleophthalmology combined with AI analysis can enable specialists to evaluate retinal images remotely and provide timely recommendations.

This approach can improve access to eye care in rural and underserved communities.

3. Advancements in Machine Learning and Imaging Technologies

Continuous advancements in deep learning algorithms and retinal imaging systems are creating opportunities for more accurate and efficient screening platforms. Improved image recognition capabilities can enhance disease detection and support personalized patient management.

Future AI solutions may provide more detailed assessments of disease progression and treatment response.

4. Increasing Healthcare Investment in Digital Transformation

Healthcare organizations in the U.S. are investing heavily in digital transformation initiatives aimed at improving efficiency and patient care. AI-based diagnostic tools align with these goals by reducing screening barriers, optimizing clinical workflows, and supporting data-driven decision-making.

Growing investment in healthcare automation is expected to create additional growth opportunities.

Key Market Trends

Several trends are shaping the future of the U.S. AI diabetic retinopathy screening market. The adoption of autonomous AI diagnostic systems is increasing as regulatory approvals and clinical validation improve confidence in these technologies.

Healthcare providers are also focusing on integrating AI solutions with existing ophthalmology workflows to enhance productivity. Additionally, cloud-based platforms are gaining popularity due to their ability to support remote monitoring, centralized data management, and scalable screening programs.

The combination of AI, digital imaging, and telemedicine is expected to create a more accessible and efficient diabetic eye care ecosystem.

Regional Analysis

Northeast United States

The Northeast region represents a significant market due to the presence of advanced healthcare institutions, strong research capabilities, and high adoption of innovative medical technologies. Major healthcare centers in this region are actively exploring AI applications to improve diagnostic efficiency and patient care.

Midwest United States

The Midwest region is witnessing increasing adoption of AI diabetic retinopathy screening solutions as healthcare providers focus on expanding access to preventive care. AI technologies are particularly valuable in addressing specialist shortages and improving screening availability in smaller communities.

South United States

The Southern region represents a strong growth area due to the high prevalence of diabetes. Increasing demand for early disease detection, expanding healthcare infrastructure, and growing awareness about diabetic eye complications are supporting the adoption of AI screening technologies.

West United States

The Western region continues to drive innovation through strong technology adoption, healthcare digitalization, and investment in artificial intelligence applications. The presence of technology-focused healthcare organizations supports the development and implementation of advanced AI screening solutions.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/us-ai-diabetic-retinopathy-screening-market

Key Companies

• AEYE Health Ltd.
• Altris AI Inc.
• Annexa Inc.
• Digital Diagnostics Inc.
• Eyenuk Inc.
• Google Health (Verily Life Sciences LLC)
• IDx Technologies Inc.
• Optomed Plc
• Retinal AI Ltd.
• RetinaLyze A/S
• Topcon Healthcare Inc.
• Voxeleron LLC

nies are focusing on AI algorithm development, retinal imaging advancements, regulatory approvals, and partnerships with healthcare providers to strengthen their market presence.

Conclusion

The U.S. AI Diabetic Retinopathy Screening market is set for substantial growth as artificial intelligence continues to transform diabetic eye care. Increasing diabetes prevalence, rising demand for early diagnosis, expanding telemedicine adoption, and advancements in machine learning technologies are creating strong opportunities for market expansion.

More Trending Latest Reports By Polaris Market Research:

Diabetes Device Market

Surgical Headlights Market

Europe Veterinary Clinical Trials Market

U.S. Molecular Biology Enzymes, Reagents And Kits Market

Regenerative Medicines Market

E-Prescribing Market

Metastatic Lung Adenocarcinoma Treatment Market

U.S. Neurovascular Intervention Devices Market